UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 23, 2006
Date of Report (Date of Earliest Event Reported)
ALLERGAN, INC.
(Exact name of Registrant as Specified in its Charter)
| |
|
|
|
|
Delaware
(State of Incorporation)
|
|
1-10269
(Commission File Number)
|
|
95-1622442
(IRS Employer
Identification Number) |
2525 Dupont Drive
Irvine, California 92612
(Address of Principal Executive Offices) (Zip Code)
(714) 246-4500
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Amendment No. 2
This form 8-K/A is filed as a further amendment (Amendment No. 2) to the Current Report on Form 8-K
filed by Allergan, Inc. (“Allergan”) on March 23, 2006 under Items 1.01, 2.01, 2.03 and 9.01 and
amended by Allergan on a Form 8-K/A filed on June 6, 2006 under Items 2.01 and 9.01. This Amendment
No. 2 is being filed by Allergan to provide certain updated pro forma financial information.
Item 9.01. Financial Statements and Exhibits.
| (a) |
|
Pro forma financial information |
| |
| |
|
The unaudited pro forma combined condensed statement of earnings with respect to the transaction
described in Item 2.01 under the Current Report on Form 8-K filed by Allergan on March 23, 2006 is
filed as Exhibit 99.2 to this Amendment No. 2 and incorporated herein by this reference. |
2